Trending...
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
The results of the study, which took place in conjunction with the ChromaDex External Research Program (CERP) and ScandiBio Therapeutics, build on findings from Phase 2 clinical data published in October 2020. The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.
The randomized, placebo-controlled, and double-blind Phase 3 clinical trial studied 309 outpatients at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey. Patients were randomly assigned on a 3:1 basis to receive the nutritional protocol or placebo in combination with the Turkish standard of care hydroxychloroquine (HCQ) or favipiravir (FP). Patients received standard of care for 5 days and the nutritional protocol or placebo for 14 days. Clinical status was evaluated through daily telephone visits, and each dose of the nutritional protocol contained 1g NR, 3.73g L-carnitine tartrate, 2.55g NAC, and 12.35g serine, taken twice a day.
"Our Phase 3 data shows that the nutritional protocol significantly improves the recovery, liver health, and markers of inflammation of patients with COVID-19," says lead investigator Dr. Adil Mardinoglu, professor at KTH—Royal Institute of Technology in Sweden & King's College London. "Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and this nutritional intervention helps to remedy the stress put on the body of an infected patient."
More on The Californer
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), which is protected by ChromaDex's patent portfolio along with other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
More on The Californer
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the results of clinical studies and whether NR may reduce the recovery time of patients with mild-to-moderate COVID-19. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
The results of the study, which took place in conjunction with the ChromaDex External Research Program (CERP) and ScandiBio Therapeutics, build on findings from Phase 2 clinical data published in October 2020. The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.
The randomized, placebo-controlled, and double-blind Phase 3 clinical trial studied 309 outpatients at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey. Patients were randomly assigned on a 3:1 basis to receive the nutritional protocol or placebo in combination with the Turkish standard of care hydroxychloroquine (HCQ) or favipiravir (FP). Patients received standard of care for 5 days and the nutritional protocol or placebo for 14 days. Clinical status was evaluated through daily telephone visits, and each dose of the nutritional protocol contained 1g NR, 3.73g L-carnitine tartrate, 2.55g NAC, and 12.35g serine, taken twice a day.
"Our Phase 3 data shows that the nutritional protocol significantly improves the recovery, liver health, and markers of inflammation of patients with COVID-19," says lead investigator Dr. Adil Mardinoglu, professor at KTH—Royal Institute of Technology in Sweden & King's College London. "Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and this nutritional intervention helps to remedy the stress put on the body of an infected patient."
More on The Californer
- Luxury Auto Detailing Brings High-End Mobile Car Care to Cherry Valley and Surrounding Areas
- Transgender Visual Artist Debuts New Work
- Stay Cool All Day With BGMgirl Drawstring Half Wigs
- California: Governor Newsom proclaims Independence Day 2025
- Gundam GQuuuuuuX Takes Center Stage at Anime Expo 2025
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), which is protected by ChromaDex's patent portfolio along with other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
More on The Californer
- John Duffy Competes in Mr Muscle Beach
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Thorn & Bloom Magazine Unveils Groundbreaking Second Edition: "Breaking the Cycle"
- Cheap O SMS Launches Groundbreaking Free SMS API Service
- California: Governor Newsom signs legislation 7.3.25
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the results of clinical studies and whether NR may reduce the recovery time of patients with mild-to-moderate COVID-19. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Filed Under: Business
0 Comments
Latest on The Californer
- Countrywide Fence Rental Expands its Temporary Fence Rental Business in Minnesota Area
- A Shepherd's Legacy: Honoring the Life and Impact of Pastor Ross Reinman
- California: Here's how President Trump's tax cuts for the ultra-rich will hurt YOU
- New Media Film Festival Announces Winners
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- DetailAxis Unveils it's 'Business Engine': Powerful AI Systems for Auto Appearance Pros
- California: Governor Newsom announces appointments 7.2.25
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Governor Newsom marks historic expansion of California's Film and Television Tax Credit Program, announces 16 new projects to film in the Golden State
- Talar Guedikian Named Winner of 2025 AAJ Paralegal of the Year Award, Sponsored by Advocate Capital
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- California: Did gas prices go up by 65 cents at the pump? No.
- Snell & Wilmer Welcomes Associate Victoria Cendejas to the Orange County Office
- Crime in California drops again — state records second-lowest homicide rate since 1966